TTIPF (Thiogenesis Therapeutics) Short Percentage of Float


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TTIPF vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Thiogenesis Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Short Percentage of Float falls into.


TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price